News Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Delayed Nyse Other stock markets 21:00:03 13/02/2026 GMT			5-day change	1st Jan Change
166.94 ^USD	-1.13%		-10.96%	-25.94%

02-13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW
02-13	Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week	RE

All News

02-13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW
02-13	Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week	RE
02-13	US prescriptions for Novo's Wegovy pill were 38,220 (not '38,909') for week ended Feb 6 - IQVIA data shared by analyst shows	RE
02-10	IQVIA and Duke Clinical Research Institute announce strategic collaboration to advance clinical research in obesity and related conditions	RE
02-10	IQVIA, Duke Clinical Research Institute to Collaborate on Obesity Research	MT
02-10	IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions	CI
02-10	IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions	BU
02-06	UBS Adjusts Price Target on IQVIA to $240 From $280, Maintains Buy Rating	MT
02-06	Leerink Partners Adjusts Price Target on IQVIA Holdings to $228 From $256, Maintains Outperform Rating	MT
02-06	Evercore ISI Adjusts Price Target on IQVIA Holdings to $225 From $250, Maintains Outperform Rating	MT
02-06	BMO Capital Adjusts Price Target on IQVIA Holdings to $250 From $260, Maintains Outperform Rating	MT
02-06	Barclays Adjusts IQVIA Price Target to $210 From $230, Maintains Equal Weight Rating	MT
02-06	JPMorgan Adjusts IQVIA Price Target to $225 From $255, Maintains Overweight Rating	MT
02-06	Citigroup Adjusts IQVIA Price Target to $200 From $230, Maintains Neutral Rating	MT
02-06	Jefferies Adjusts Price Target on IQVIA Holdings to $255 From $270, Maintains Buy Rating	MT
02-06	Stifel Adjusts Price Target on IQVIA Holdings to $220 From $273, Maintains Buy Rating	MT
02-06	Gland Pharma Gets US FDA's Nod for Zoledronic Acid Injection	MT
02-05	IQVIA backs AI strategy as analysts question impact on business	RE
02-05	IQVIA Shares Fall After 2026 EPS Guidance Miss Expectations	MT
02-05	IQVIA forecasts weak annual profit on higher interest expenses	RE
02-05	IQVIA Holdings Inc., Q4 2025 Earnings Call, Feb 05, 2026
02-05	IQVIA Holdings Inc. Provides Earnings Guidance for Full Year 2026	CI
02-05	Iqvia shares down 6.48% after co forecasts 2026 profit below estimates	RE
02-05	IQVIA Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-05	IQVIA Q4 Adjusted Earnings, Revenue Rise; Issues 2026 Guidance	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

All News

Filters